Creation of Innovative Pharmaceuticals for Intractable and Rare Diseases
First written in FY2016. 8 of 13 entries say "Advanced", first in FY2020. Latest entry: FY2026.
0 other companies' latest entry also says "Other".
- FY2026Update to clinical trial initiation resultsAnnual report
「Number of clinical trials initiated (target: 5 products by FY2027): 0 products (total of 2 products from FY2023 through FY2025)」
Against the target of 5 products by FY2027, the company disclosed that 0 products entered clinical trials in FY2025, bringing the cumulative total from FY2023 through FY2025 to 2 products. - FY2025AdvancedAnnual report
「Number of clinical trials initiated (target: 5 products by FY2027): 2 products」
In the rare disease field, the company disclosed an FY2024 result of 2 products against the target of initiating clinical trials for 5 products by FY2027. The result increased from the 1 product disclosed previously. - FY2024AdvancedAnnual report
「Over the 5-year period from FY2023 through FY2027, we aim to initiate clinical trials for a total of 5 lysosomal disease treatments and will continue to make steady progress toward this goal.」
The company set the specific goal of initiating clinical trials for a total of 5 products over the 5 years from FY2023 through FY2027. The FY2023 result was 1 product. - FY2023AdvancedAnnual report
「We are currently focusing on the research and development of new medicines using our proprietary blood-brain barrier-penetration technology, J-Brain Cargo®, for more than 17 types of lysosomal diseases.」
The company gave concrete form to its mission of creating innovative medicines for intractable and rare diseases through a pipeline of more than 17 products, the launch of IZCARGO®, global clinical development of multiple products and a policy of early commercialization. - FY2022AdvancedAnnual report
「We are currently focusing on the research and development of new medicines using our proprietary blood-brain barrier-penetration technology, J-Brain Cargo®, for more than 17 types of lysosomal diseases.」
The company gave concrete form to its goal of creating innovative medicines for intractable and rare diseases by expanding the number of products using J-Brain Cargo® to more than 17, launching IZCARGO® and starting development of JR-479. - FY2021AdvancedAnnual report
「In FY2020, the first year of Transformation, the company obtained marketing approval in Japan for IZCARGO®, a treatment for Hunter syndrome, and achieved significant progress in research and development.」
The company gave concrete form to its policy of creating innovative medicines for intractable and rare diseases by obtaining approval for IZCARGO® and focusing on a group of lysosomal disease treatments using J-Brain Cargo®. - FY2020AdvancedAnnual report
「During the period of the medium-term management plan Transformation, we will focus on the research and development of a series of lysosomal disease treatments using J-Brain Cargo®, including the Hunter syndrome treatment JR-141.」
The company placed greater emphasis on its mission of creating innovative medicines for intractable and rare diseases by making lysosomal disease treatments using J-Brain Cargo® the core of its 3-year medium-term plan. - FY2019RestatedAnnual report
「Our mission, under the corporate philosophy of contributing to people's health through pharmaceuticals, is to deliver innovative medicines for intractable and rare diseases to patients.」
The company reaffirmed its mission to deliver innovative medicines for intractable and rare diseases to patients. - FY2017RestatedAnnual report
「In our pharmaceutical business, based on the biotechnology and cell culture technologies cultivated over many years, our group is engaged in the research and development of innovative pharmaceuticals and regenerative medicine products for intractable and rare diseases, particularly in the pediatric field.」
The company reaffirmed its mission to create innovative pharmaceuticals and regenerative medicine products for intractable and rare diseases, particularly in the pediatric field. - FY2016First statedAnnual report
「Our mission, under the corporate philosophy of contributing to people's health through pharmaceuticals, is to create innovative medicines for intractable and rare diseases.」
The company clearly states that creating innovative medicines for intractable and rare diseases is its mission based on its corporate philosophy.